These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9141377)

  • 1. Association of calcium channel blocker use with increased rate of acute myocardial infarction in patients with left ventricular dysfunction.
    Kostis JB; Lacy CR; Cosgrove NM; Wilson AC
    Am Heart J; 1997 May; 133(5):550-7. PubMed ID: 9141377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials.
    Vermes E; Tardif JC; Bourassa MG; Racine N; Levesque S; White M; Guerra PG; Ducharme A
    Circulation; 2003 Jun; 107(23):2926-31. PubMed ID: 12771010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Ojeifo O; Wiviott SD; Antman EM; Murphy SA; Udell JA; Bates ER; Mega JL; Sabatine MS; O'Donoghue ML
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1275-81. PubMed ID: 24239201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement.
    Hager WD; Davis BR; Riba A; Moye LA; Wun CC; Rouleau JL; Lamas GA; Pfeffer MA
    Am Heart J; 1998 Mar; 135(3):406-13. PubMed ID: 9506325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.
    Benedict CR; Shelton B; Johnstone DE; Francis G; Greenberg B; Konstam M; Probstfield JL; Yusuf S
    Circulation; 1996 Aug; 94(4):690-7. PubMed ID: 8772689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD).
    Knight EL; Glynn RJ; McIntyre KM; Mogun H; Avorn J
    Am Heart J; 1999 Nov; 138(5 Pt 1):849-55. PubMed ID: 10539815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction.
    Domanski MJ; Mitchell GF; Norman JE; Exner DV; Pitt B; Pfeffer MA
    J Am Coll Cardiol; 1999 Mar; 33(4):951-8. PubMed ID: 10091821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients.
    Costanzo P; Perrone-Filardi P; Petretta M; Marciano C; Vassallo E; Gargiulo P; Paolillo S; Petretta A; Chiariello M
    J Hypertens; 2009 Jun; 27(6):1136-51. PubMed ID: 19451836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction.
    Kostis JB
    Am J Hypertens; 1995 Sep; 8(9):909-14. PubMed ID: 8541006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
    Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
    Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction.
    Alsheikh-Ali AA; Wang PJ; Rand W; Konstam MA; Homoud MK; Link MS; Estes NA; Salem DN; Al-Ahmad AM
    Am Heart J; 2004 Jun; 147(6):1061-5. PubMed ID: 15199356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial infarction in newly diagnosed hypertensive Medicaid patients free of coronary heart disease and treated with calcium channel blockers.
    Leader SG; Mallick R; Briggs NC
    Am J Med; 1997 Feb; 102(2):150-7. PubMed ID: 9217564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.
    Estacio RO; Jeffers BW; Hiatt WR; Biggerstaff SL; Gifford N; Schrier RW
    N Engl J Med; 1998 Mar; 338(10):645-52. PubMed ID: 9486993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN).
    Fonarow GC; Lukas MA; Robertson M; Colucci WS; Dargie HJ
    Am Heart J; 2007 Oct; 154(4):637-44. PubMed ID: 17892984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).
    Vermes E; Ducharme A; Bourassa MG; Lessard M; White M; Tardif JC;
    Circulation; 2003 Mar; 107(9):1291-6. PubMed ID: 12628950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators.
    Konstam V; Salem D; Pouleur H; Kostis J; Gorkin L; Shumaker S; Mottard I; Woods P; Konstam MA; Yusuf S
    Am J Cardiol; 1996 Oct; 78(8):890-5. PubMed ID: 8888661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction.
    Ishani A; Weinhandl E; Zhao Z; Gilbertson DT; Collins AJ; Yusuf S; Herzog CA
    J Am Coll Cardiol; 2005 Feb; 45(3):391-9. PubMed ID: 15680718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.
    Böhm M; Pogue J; Kindermann I; Pöss J; Koon T; Yusuf S
    Eur J Heart Fail; 2014 Mar; 16(3):325-33. PubMed ID: 24464788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
    Stephenson K; Skali H; McMurray JJ; Velazquez EJ; Aylward PG; Kober L; Van de Werf F; White HD; Pieper KS; Califf RM; Solomon SD; Pfeffer MA
    Heart Rhythm; 2007 Mar; 4(3):308-13. PubMed ID: 17341394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.